CLINICAL TRIALS PROFILE FOR DIATRIZOATE-60

All Clinical Trials for DIATRIZOATE-60

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00953199 ↗	Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis	Completed	Milton S. Hershey Medical Center	N/A	2010-03-01	The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.
NCT00953199 ↗	Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis	Completed	Abraham Mathew MD	N/A	2010-03-01	The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.
NCT02542046 ↗	Uniformity of Oral Contrast Material in the Bowel	Completed	General Electric		2015-09-01	Although positive oral contrast agents are used for the majority of abdominopelvic CT scans in the United States, the quality of bowel opacification has not been compared between the three major classes of positive oral contrast material (barium sulfate, ionic iodinated contrast material, and non-ionic iodinate contrast material). This is a retrospective single institution study of clinical records to show whether the uniformity of bowel opacification is different between the three main types of positive CT oral contrast material used in the United States (Barium sulfate, Diatrizoate, and Iohexol). The investigators will retrospectively identify 250 patients each who received oral barium sulfate, diatrizoate, and iohexol for CT scanning of the abdomen and pelvis (total 750 patients) and assess the quality of bowel lumen opacification by the positive oral contrast agents.
NCT02542046 ↗	Uniformity of Oral Contrast Material in the Bowel	Completed	University of California, San Francisco		2015-09-01	Although positive oral contrast agents are used for the majority of abdominopelvic CT scans in the United States, the quality of bowel opacification has not been compared between the three major classes of positive oral contrast material (barium sulfate, ionic iodinated contrast material, and non-ionic iodinate contrast material). This is a retrospective single institution study of clinical records to show whether the uniformity of bowel opacification is different between the three main types of positive CT oral contrast material used in the United States (Barium sulfate, Diatrizoate, and Iohexol). The investigators will retrospectively identify 250 patients each who received oral barium sulfate, diatrizoate, and iohexol for CT scanning of the abdomen and pelvis (total 750 patients) and assess the quality of bowel lumen opacification by the positive oral contrast agents.

Clinical Trial Conditions for DIATRIZOATE-60

Condition Name

Condition Name for DIATRIZOATE-60
Intervention	Trials
Known or Suspected Abdominal Disease	1
Pancreatitis	1

Condition MeSH

Condition MeSH for DIATRIZOATE-60
Intervention	Trials
Pancreatitis	1

Clinical Trial Locations for DIATRIZOATE-60

Trials by Country

Trials by Country for DIATRIZOATE-60
Location	Trials
United States	2

Trials by US State

Trials by US State for DIATRIZOATE-60
Location	Trials
California	1
Pennsylvania	1

Clinical Trial Progress for DIATRIZOATE-60

Clinical Trial Phase

Clinical Trial Phase for DIATRIZOATE-60
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for DIATRIZOATE-60
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for DIATRIZOATE-60

Sponsor Name

Sponsor Name for DIATRIZOATE-60
Sponsor	Trials
Milton S. Hershey Medical Center	1
Abraham Mathew MD	1
General Electric	1

Sponsor Type

Sponsor Type for DIATRIZOATE-60
Sponsor	Trials
Other	3
Industry	1